SELLAS Life Sciences Group Stock Forecast
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 11.26 -0.02%
SLS analyst consensus
Consensus (2 analysts)
none
Avg. price target
$32.50+188.63%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering SELLAS Life Sciences Group (2026-10-07), 2 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $32.50, with a high estimate of $35.00 and a low estimate of $30.00. The average target implies upside of 188.6% from the current price of $11.26.
The spread between the highest and lowest targets is 16.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SLS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 50% |
| Buy | 1 | 50% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | +166.43% |
| Average target | $32.50 | +188.63% |
| High target | $35.00 | +210.83% |